

 $\epsilon$ 

IVD

# **AGTRI A1166C POLYMORPHISM**

## ORDERING INFORMATIONS

REF: GEN-011-25 RDM Code: 1737734/R Tests: 25 Reactions: 31

REF: GEN-011-50 RDM Code: 2256357/R Tests: 50 Reactions: 62

CND Code: W0106010499

Manufacturer: BioMol Laboratories s.r.l.

## CONTENTS OF THE KIT

The kit consists of: reagents for Real-Time PCR amplification \*reagents for the extraction of genomic DNA are not supplied in the kit

## PRODUCT CHARACTERISTICS

Detection of A1166C polymorphism of the gene coding for the type I angiotensin 2 receptor, AGTR1, by Real-Time PCR technique. Optimized kit for Real-Time PCR instrumentation Biorad CFX96, Biorad Opus Dx and Agilent AriaDx.

There are numerous components of this system: renin, prorenin, angiotensin converting enzyme (ACE), angiotensinogen (AGT), angiotensin I and angiotensin II; the latter represents the final effector of the reninangiotensin system and exerts its effects on the cardiovascular system through binding with specific receptors. The first step in the enzymatic cascade leading to the production of angiotensin II is the conversion of angiotensinogen to angiotensin I by the proteolytic enzyme renin. The second step in the process involves the conversion of angiotensin I to angiotensin II, via a reaction catalysed by ACE. Angiotensin II is the main active peptide of the RAAS which functions through at least four types of receptors. The AGTR1 receptor cardiovascular effects, including vasoconstriction, aldosterone synthesis, vasopressin secretion, vascular smooth muscle cell proliferation, renal blood flow, regulation of renin activity, renal sodium absorption, modulation of sympathetic nervous system activity, and cardiac function.

There are genetic polymorphisms in the various components of the RAS that may have clinical relevance. A single nucleotide polymorphism has been described for the AGTR1 gene, causing the A1166C substitution in the 3'-untranscribed region.

The presence of the C allele correlates with: a greater risk of developing arterial hypertension, being subject to cerebral stroke especially in smokers and a greater risk of recurrence of acute myocardial infarction.

§ AGT M235T polymorphism and heart failure in a cohort of Tunisian population: diagnostic and prognostic value. Int J Clin Exp Med. 2015 Sep 15;8(9):16346-51.


-2011 Aug;41(8):828-35.


## CLINICAL SIGNIFICANCE

The renin-angiotensin-aldosterone system (SRAA) is a hormonal mechanism that regulates blood pressure, circulating plasma volume, arterial muscle tone through various mechanisms and aldosterone secretion; it also plays an important role in the etiology of hypertension.

The renin-angiotensin system (SRAA) also exerts local effects on cell proliferation, apoptosis, inflammation and angiogenesis in various tissues. Furthermore, there are data in the literature correlating SRAA with tumor tumorigenesis and angiogenesis.

Each of the SRAA-related polymorphisms, alone or in combination, may be related to increased or decreased activity of the SRAA system and thus to the physiological processes controlled by that system.













## For in vitro diagnostic use





# **AGTRI A1166C POLYMORPHISM**

## ORDERING INFORMATIONS

REF: GEN-011-25 RDM Code: 1737734/R Tests: 25 Reactions: 31 REF: GEN-011-50 RDM Code: 2256357/R Tests: 50 Reactions: 62 CND Code: W0106010499 Manufacturer: BioMol Laboratories s.r.l.

#### CONTENTS OF THE KIT

The kit consists of: reagents for Real-Time PCR amplification \*reagents for the extraction of genomic DNA are not supplied in the kit

#### CONTENTS OF THE KI

DESCRIPTION	LABEL	VOLUME		STORAGE
		GEN-011-25	GEN-011-50	
Mix oligonucleotides and probes	Mix A1166C AGTR1 10X	1 x 85 µl	1 x 170 µl	-20°C
Mix buffer and Taq polymerase enzyme	Mix Real-Time PCR 5X	1 x 170 µl	1 x 340 µl	-20°C
Deionized H <sub>2</sub> 0	Deionized H₂0	2 x 1 ml	2 x 1 ml	-20°C
Genomic DNA or recombinant DNA	Control +1	1 x 22 µl	1 x 22 µl	-20°C
Genomic DNA or recombinant DNA	Control +2	1 x 22 µl	1 x 22 µl	-20°C
Genomic DNA or recombinant DNA	Control +3	1 x 22 µl	1 x 22 µl	-20°C

## TECHNICAL CHARACTERISTICS

## COD. GEN-011-25 / COD. GEN-011-50

	•
STABILITY	18 months
REAGENTS STATUS	Ready to use
BIOLOGICAL MATRIX	Genomic DNA extracted from whole blood, tissue, cells
POSITIVE CONTROL	Recombinant DNA for at least 3 analytical sessions
VALIDATED INSTRUMENTS	Biorad CFX96 Dx, Biorad Opus Dx e Agilent AriaDx
TECHNOLOGY	Real-time PCR; oligonucleotides and specific probes; 2 FAM/HEX fluorescence channels
RUNNING TIME	85 min
THERMAL CYCLING PROFILE	1 cycle at 95 °C (10 min); 45 cycles at 95 °C (15 sec) + 60 °C (60 sec)
ANALYTICAL SPECIFICITY	Absence of non-specific pairings of oligonucleotides and probes; absence of cross-reactivity
ANALYTICAL SENSITIVITY: LIMIT OF DETECTION (LOD)	≥ 0,016 ng of DNA
ANALYTICAL SENSITIVITY: LIMIT OF BLANK (LOB)	0% NCN
REPRODUCIBILITY	99,9%
DIAGNOSTIC SPECIFICITY / DIAGNOSTIC SENSITIVITY	100%/98%



